Home › Research › Brain scans and imaging
Type 2 diabetes mellitus and biomarkers of neurodegeneration
Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V, Alzheimer's Disease Neuroimaging Initiative (ADNI).. Neurology, 2015-09-02
Topic: Brain proteins, microglia and lab models
Plain-language summary
Objective Our objective was to investigate whether type 2 diabetes mellitus (T2DM) influences neurodegeneration in a manner similar to Alzheimer disease (AD), by promoting brain β-amyloid (Aβ) or tau. Methods We studied the cross-sectional associations of T2DM with cortical thickness, brain Aβ load, and CSF levels of Aβ and tau in a sample of people from the Alzheimer's Disease Neuroimaging Initiative with diagnoses of AD dementia, mild cognitive impairment, and normal cognition. All (n=816) received MRI, and a subsample underwent brain amyloid imaging (n=102) and CSF Aβ and tau measurements (n=415). Analyses were performed across and within cognitive diagnostic strata. Results There were 124 people with T2DM (mean age 75.5 years) and 692 without T2DM (mean age 74.1 years). After adjusting for age, sex, total intracranial volume, APO ε4 status, and cognitive diagnosis, T2DM was associated with lower bilateral frontal and parietal cortical thickness (mL) (β=-0.03, p=0.01). T2DM was not associated with 11C Pittsburgh compound B standardized uptake value ratio (AU) in any brain region or with CSF Aβ42 levels (pg/mL). T2DM was associated with greater CSF total tau (pg/mL) (β=16.06, p=0.04) and phosphorylated tau (β=5.84, p=0.02). The association between T2DM and cortical thickness was attenuated by 15% by the inclusion of phosphorylated tau. Conclusions T2DM may promote neurodegeneration independent of AD dementia diagnosis, and its effect may be driven by tau phosphorylation. The mechanisms through which T2DM may promote tau phosphorylation deserve further study.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 816 participants. In this cross-sectional sample, type 2 diabetes was associated with thinner frontal and parietal cortex and higher CSF tau, but not with amyloid on PET or CSF amyloid levels. The study cannot establish cause and effect, and it does not show that treating diabetes prevents or cures Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Moran, C., Beare, R., Phan, T. G., Bruce, D. G., Callisaya, M. L., & Srikanth, V. (2015). Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. https://doi.org/10.1212/wnl.0000000000001982
Vancouver
Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015. doi:10.1212/wnl.0000000000001982. PMID: 26333802.
BibTeX
@article{moran2015-26333802,
author = {Moran, C. and Beare, R. and Phan, T. G. and Bruce, D. G. and Callisaya, M. L. and Srikanth, V.},
title = {{Type 2 diabetes mellitus and biomarkers of neurodegeneration}},
journal = {Neurology},
year = {2015},
doi = {10.1212/wnl.0000000000001982},
pmid = {26333802},
url = {https://doi.org/10.1212/wnl.0000000000001982}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results There were 124 people with T2DM (mean age 75.5 years) and 692 without T2DM (mean age 74.1 years).
- After adjusting for age, sex, total intracranial volume, APO ε4 status, and cognitive diagnosis, T2DM was associated with lower bilateral frontal and parietal cortical thickness (mL) (β=-0.03, p=0.01).
- T2DM was not associated with 11C Pittsburgh compound B standardized uptake value ratio (AU) in any brain region or with CSF Aβ42 levels (pg/mL).
- T2DM was associated with greater CSF total tau (pg/mL) (β=16.06, p=0.04) and phosphorylated tau (β=5.84, p=0.02).
Why it matters
In this cross-sectional sample, type 2 diabetes was associated with thinner frontal and parietal cortex and higher CSF tau, but not with amyloid on PET or CSF amyloid levels. The study cannot establish cause and effect, and it does not show that treating diabetes prevents or cures Alzheimer's.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Study designcross-sectional
- Participants816
- Evidence strengthLow
How this study scored 61/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 816 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 297 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 22.8 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 4 / 6 | Cited 18.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 17 other studies in this library |
| Still being cited | 3 / 4 | Cited 69 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Velandai K. Srikanth: h-index 72 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Monash University: institution h-index 1,146 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26333802) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000001982
- PubMed: 26333802
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain scans and imaging from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.